# Basic Pharma

produces tag-free recombinant human serum albumin (rHSA) expressed in Hansenula polymorpha yeast, in collaboration with ARTES Biotechnology (Langenfeld, Germany) — the joint product launched at BIO-Europe (October 30, 2024);…

Source: https://en.bioecon.ru/companies/basic-pharma/
Updated: 2026-08-15

- Country: Netherlands

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Acquisition funding round by SHS Capital on July 14, 2026 | https://basicpharma.nl/blogs/press-release-basic-pharma-takes-next-step-in-growth-strategy-with-shs-capital |
| Capacity | Bioreactor capacity up to 50 L for small and pilot scale fermentation | https://basicpharma.nl/custom-recombinant-protein-services |
| Certification | ISO 13485:2016 certified and GMP-compliant facility | https://basicpharma.nl/about-us, https://www.bio-connect.nl/news/basic-pharma-local-recombinant-rhsa-animal-free/ |
| Production site | Geleen, the Netherlands | https://basicpharma.nl/about-us, https://www.bio-connect.nl/news/basic-pharma-local-recombinant-rhsa-animal-free/ |
| Headcount | More than 100 employees; reported as 101 employees | https://basicpharma.nl/about-us |

Independent sources: bio-connect.nl

## Technologies

- [Recombinant human serum albumin (rHSA)](https://en.bioecon.ru/technology/recombinant-human-serum-albumin/)